Spectrum of Neurological Disorders Undergoing Plasmapheresis in a Tertiary Care Hospital

Muhammad  Nawaz; Khalid  Sher; Huma  Khan

doi:10.54112/bcsrj.v6i3.1584

Authors

Muhammad Nawaz Department Of Neurology, Jinnah Postgraduate Medical Centre Karachi, Pakistan
Khalid Sher Department Of Neurology, Jinnah Postgraduate Medical Centre Karachi, Pakistan
Huma Khan Department Of Neurology, Zubaida Medical Centre Karachi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i3.1584

Keywords:

Neurological disorder, plasmapheresis, GBS, MG

Abstract

Plasmapheresis is a therapeutic modality widely used in various immune-mediated neurological disorders. Understanding the clinical characteristics, disease spectrum, and treatment outcomes in patients undergoing plasmapheresis can help optimize its use in neurology. Objective: To analyze the demographic characteristics, clinical profile, comorbid conditions, laboratory parameters, and outcomes of patients with neurological disorders treated with plasmapheresis at a tertiary care hospital. Methods: A cross-sectional study was conducted in Ward 28, Department of Neurology, Jinnah Postgraduate Medical Centre (JPMC), Karachi, from November 15, 2024, to February 15, 2025, after obtaining ethical approval. A total of 145 patients aged 15–70 years, of either gender, presenting with suspected neurological diseases and undergoing plasmapheresis, were enrolled using non-probability consecutive sampling. Clinical presentations, diagnoses, and outcomes were recorded and analyzed. Results: The mean age of patients was 40.1 ± 15.6 years, with an average height of 1.7 ± 0.14 meters and weight of 74.11 ± 14.1 kg. Weakness and pain were the most common presenting symptoms, each reported in 72 patients (49.65%). The most frequently diagnosed condition was Guillain-Barré Syndrome (GBS) in 77 patients (53.10%), followed by Myasthenia Gravis (MG) in 36 (24.83%), Neuromyelitis Optica Spectrum Disorder (NMOSD) in 22 (15.17%), and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) in 10 patients (6.90%). Conclusion: The findings highlight Guillain-Barré Syndrome as the most common neurological condition requiring plasmapheresis. Variations in demographic and clinical features emphasize the need for localized data to inform diagnostic accuracy and therapeutic strategies in immune-mediated neurological disorders.

Downloads

References

Siriratnam P, Huda S, Butzkueven H, van der Walt A, Jokubaitis V, Monif M. A comprehensive review of advances in neuromyelitis optica spectrum disorder. Autoimmunity Reviews. 2023; 22(12):103465.

Hussein G, Liu B, Yadav SK, Warsame M, Jamil R, Surani SR, et al. Plasmapheresis in the ICU. Medicine (Kaunas, Lithuania). 2023; 59(12).

Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, et al. The Global Burden of Neurological Disorders: Translating Evidence into Policy. The Lancet Neurology. 2020; 19(3):255-65.

Iqbal R, Asad MJ, Shah MB, Mahmood RT, Siddiqi S. Clinical and biochemical profile of Guillain-Barré Syndrome in Pakistan. Neurosciences (Riyadh, Saudi Arabia). 2021; 26(3):242-7.

Gilhus NE. Chapter 27 - Myasthenia gravis and congenital myasthenic syndromes. In: Younger DS, editor. Handbook of Clinical Neurology. 195: Elsevier; 2023. p. 635-52.

Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology. 2024; 271(1):141-76.

Lin Y, Oji S, Miyamoto K, Narita T, Kameyama M, Matsuo H. Real-world application of plasmapheresis for neurological disease: Results from the Japan-Plasmapheresis Outcome and Practice Patterns Study. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, and the Japanese Society for Dialysis Therapy. 2023; 27(1):123-35.

Kazmi SS, Alamgir W, Hashmat A, Yousaf A, Nawaz KH, and Hassan Z. Plasmapheresis in Neurological Disorders: Frequency and Type of Adverse Effects Associated with this Procedure in Atertiary Care Hospital in Pakistan. Pakistan Armed Forces Medical Journal. 2022; 72(SUPPL-2):S389-92.

Fukuoka K, Kishimoto M, Kawakami T, Komagata Y, Kaname S. Plasmapheresis for systemic vasculitis. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, and the Japanese Society for Dialysis Therapy. 2022; 26(3):493-506.

Ipe TS, Davis AR, Raval JS. Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence. Frontiers in neurology. 2021; 12:662856.

Ahmad SS, Koncsol SW. Cultural Factors Influencing Mental Health Stigma: Perceptions of Mental Illness (POMI) in Pakistani Emerging Adults. Religions. 2022; 13(5):401.

Ayaz ul Haq M, Nabi D, Khan MO, Ullah R, Junaid M, Nasarullah HM. Frequency, Age, Gender Distribution, and Seasonal Variation of Guillain-Barré Syndrome in a Province of Pakistan: A Retrospective Study: Prevalance of Guillain-Barre Syndrome. Pakistan Journal of Health Sciences. 2023; 4(03):207-10.

McCombe PA, Hardy TA, Nona RJ, Greer JM. Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and experimental autoimmune neuritis. Frontiers in immunology. 2022; 13:1038411.

Miyazaki Y, Niino M, Sakushima K, Takahashi E, Naganuma R, Amino I, et al. Association of Smoking and Generalized Manifestations of Myasthenia Gravis. Internal medicine (Tokyo, Japan). 2022; 61(11):1693-8.

Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP, Jacobs BC. Guillain–Barré syndrome in low- and middle-income countries: Challenges and prospects. Nature Reviews Neurology. 2021; 17(5):285-96.

Fujihara K, Cook LJ. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics. Current opinion in neurology. 2020; 33(3):300-8.

Balili K, Louhab N, Adarmouch L, Chraa M, Hachimi A, Belbachir A, et al. Guillain–Barre syndrome: small-volume plasmapheresis versus intravenous immunoglobulin—3rd level hospital experience. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2024; 60(1):45.

Zaki HA, Iftikhar H, Najam M, Masood M, Al-Marri NDR, Elgassim MAM, et al. Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis. eNeurologicalSci. 2023; 31:100468.

Zheng P, Tian DC, Xiu Y, Wang Y, Shi FD. Incidence of Guillain-Barré syndrome (GBS) in China: A national population-based study. The Lancet Regional Health Western Pacific. 2022; 18:100302.